scispace - formally typeset
Open AccessJournal ArticleDOI

Evaluation of Leishmanization Using Iranian Lizard Leishmania Mixed With CpG-ODN as a Candidate Vaccine Against Experimental Murine Leishmaniasis.

TLDR
Mice immunized with ILL+CpG were protected against the development of the dermal lesion and showed a significant reduction in the parasite load, in comparison to the control groups, indicating that ILL with an appropriate adjuvant would be a suitable choice for vaccination against leishmaniasis.
Abstract
Background and Objectives: The live non-pathogenic Leishmania tarantolae has recently provided a promising approach as an effective vaccine candidate against experimental leishmaniasis (ILL). Here, we evaluated the immunoprotective potential of the live Iranian Lizard Leishmania mixed with CpG adjuvant against L. major infection in BALB/c mice. Methods: Four groups of female BALB/c mice were included in the study. The first and second groups received PBS and CpG, respectively. The immunized groups received 2 × 105 ILL promastigotes and the CpG-mixed ILL (ILL+CpG). Injections were performed subcutaneously in the right footpad. Three weeks later, all mice were challenged with 2 × 105 metacyclic promastigotes of Leishmania major EGFP ; inoculation was done in the left footpad. The measurement of footpad swelling and in vivo fluorescent imaging were used to evaluate disease progress during infection course. Eight weeks after challenge, all mice were sacrificed and the cytokines levels (IFN-γ, IL-4, and IL-10) and sera antibodies concentrations (IgG2a and IgG1) using ELISA assay, nitric oxide production using Griess assay, and arginase activity in cultured splenocytes, were measured. In addition, direct fluorescent microscopy analysis and qPCR assay were used to quantify the splenic parasite burden. Result: The results showed that mice immunized with ILL+CpG were protected against the development of the dermal lesion. Moreover, they showed a significant reduction in the parasite load, in comparison to the control groups. The observed protection was associated with higher production of IFN-γ, as well as a reduction in IL-4 level. Additionally, the results demonstrated that arginase activity was decreased in ILL+CpG group compared to other groups. Conclusion: Immunization using ILL+CpG induces a protective immunity; indicating that ILL with an appropriate adjuvant would be a suitable choice for vaccination against leishmaniasis.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Leishmania tarentolae: A new frontier in the epidemiology and control of the leishmaniases

TL;DR: The systematics and biology of L. tarentolae in the insect vectors and the vertebrate hosts are discussed and questions about evolution of reptilian leishmaniae are addressed.
Journal ArticleDOI

Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice.

TL;DR: In this article, the authors evaluated gardiquimod (a toll-like receptor-7 agonist) for its action as an adjuvant with the heat-killed antigen of Leishmania donovani.
Journal ArticleDOI

A candidate vaccine composed of live nonpathogenic Iranian Lizard Leishmania mixed with Chitin microparticles protects mice against Leishmania major infection

- 01 Mar 2022 - 
TL;DR: In this paper , the effect of leishmanization using ILL mixed with chitin microparticles (CMPs) as an adjuvant against L. major infection in BALB/c mice was reported.
Journal ArticleDOI

Leishmania tarentolae as Potential Live Vaccine Co-Expressing Distinct Salivary Gland Proteins Against Experimental Cutaneous Leishmaniasis in BALB/c Mice Model

TL;DR: This is the first study demonstrating the potency of a safe live vaccine based on the combination of different salivary proteins against the infectious challenge with two different species of Leishmania.
Journal ArticleDOI

Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein

TL;DR: The results indicate that L. tarentolae could be used as a vehicle for antigen delivery to DCs and to induce the maturation of these cells, and a limited release of Th1 cytokines was observed after parasite infection, suggesting L.Tarentolai as a neutral vaccine vehicle that could be administered in association with appropriate immune-modulating molecules.
References
More filters
Journal ArticleDOI

Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs

TL;DR: The candidate vaccine elicited an immune activation status potentially compatible with effective control of the etiological agent of CVL, as indicated by the intense cell proliferation and increased nitric oxide production during in vitro stimulation by L. chagasi soluble antigens.
Journal ArticleDOI

Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.

TL;DR: This study is the first to use a combination of recombinant L. tarentolae together with a sand fly salivary antigen as a vaccine strategy against L. major infection and represents a novel promising vaccination approach against leishmaniasis.
Journal ArticleDOI

Adjuvants for Leishmania vaccines: from models to clinical application

TL;DR: Adjuvant studies have helped to unveil the requirement for certain types of immune responses at specific stages of CL disease and provide a basis to aid the design of effective second-generation vaccines for human CL.
Journal ArticleDOI

A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs

TL;DR: The observed interaction between potential antigen-presenting cells and lymphocyte activation status indicated a relationship between innate and adaptive immune responses, and the higher frequency in L. chagasi antigen-specific CD8+ T-lymphocytes showed a profile compatible with anti-CVL vaccine potential.
Related Papers (5)